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The use of serial serum measurements of the carbohydrate antigen 19-9 (CA19-9) to guide treatment decisions and serve as a
surrogate end point in clinical trial design requires further validation. We investigated whether CA19-9 decline represents an accurate
surrogate for survival and time to treatment failure (TTF) in a cohort of 76 patients with advanced pancreatic cancer receiving fixed-
dose rate gemcitabine in three separate studies. Statistically significant correlations between percentage CA19-9 decline and both
overall survival and TTF were found, with median survival ranging from 12.0 months for patients with the greatest degree of
biomarker decline (475%) compared with 4.3 months in those whose CA19-9 did not decline during therapy (Po0.001). Using
specific thresholds, patients with X25% decline in CA19-9 during treatment had significantly better outcomes than those who did
not (median survival and TTF of 9.6 and 4.6 months vs 4.4 and 1.5 months; Po0.001). Similar results were seen using both 50 and
75% as cutoff points. We conclude that serial CA19-9 measurements correlate well with clinical outcomes in this patient population,
and that decline in this biomarker should be entertained for possible use as a surrogate end point in clinical trials for the selection of
new treatments in this disease.
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Pancreatic cancer represents the fourth leading cause of cancer-
associated mortality in the United States, with the annual mortality
rate approximating the incidence rate (Jemal et al, 2005). Clinical
trials of novel therapeutic agents in this disease often report
response rate as a study end point, but the usefulness and accuracy
of this outcome variable are debatable. First of all, the ability to
monitor objective responses to systemic therapy in patients with
advanced pancreatic cancer, particularly at the primary pancreatic
site, can be difficult using conventional methods such as
computerised tomography. Measurement of objective response
by formal RECIST criteria does not allow one to gauge accurately
the true burden of disease due to the extensive desmoplasia and
surrounding inflammation associated with pancreatic tumours and
the inability to trace clearly defined tumour margins of the
primary pancreatic lesion (Rothenberg et al, 1996). Furthermore,
promising response rates in early trials do not uniformly translate
into significant improvement in patient outcomes when investi-
gated in phase III studies. Hence, alternative methods for
monitoring patients on therapy are critical for guiding early
treatment decisions, offering prognostic information, and imple-
menting into clinical trial design as new surrogate end points for
the selection of therapeutic agents.
Carbohydrate antigen 19-9 (CA19-9) is the sialylated Lewis blood
group antigen originally defined by the monoclonal antibody 1116
NS 19-9 (Koprowski et al, 1979, 1981). A radioimmunoassay was
developed for this marker in 1983 (Del Villano et al, 1983), and
since that time, measurement of CA19-9 levels in serum has been
commonly used as an adjunct in the diagnosis of pancreatic cancer.
Approximately three-quarters of all patients with pancreatic cancer
have an elevated serum CA19-9 level at baseline (Yeo et al,2 0 0 2 ) .
Patients who are genotypically negative for the Lewis blood group
antigen, however, will not express CA19-9 even in the presence of
active pancreatic cancer. Using as a cutoff point of 37Uml
 1 as the
upper limit of normal, overall sensitivity of the assay is
approximately 80% and its specificity is 90% for detecting
pancreatic cancer (Steinberg, 1990). Additionally, serial measure-
ments of CA19-9 are frequently performed for prognostic purposes,
for gauging disease relapse and activity, and for monitoring patients
undergoing therapy as an approximate surrogate for response.
Despite the frequency of its use in clinical practice, application
of the CA19-9 biomarker as a strategy to guide treatment decisions
and to serve as a primary end point in clinical trial design has not
been well established. In particular, correlation between marker
decline during chemotherapy and patient outcomes requires
further validation. This analysis investigated whether, and to what
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sdegree, CA19-9 decline represented an accurate prognostic test in a
group of study patients with advanced pancreatic cancer under-
going treatment with gemcitabine administered at fixed-dose rate
(FDR) infusion.
MATERIALS AND METHODS
This retrospective analysis pooled data from three separate studies
examining the role of gemcitabine administered at a FDR infusion
in the treatment of advanced pancreatic cancer. These three
studies included: (1) a randomised phase II study of gemcitabine
given either by FDR infusion (10mg
 1m
 2min
 1) at 1500mgm
 2
or by standard 30-min infusion at 2200mgm
 2, given on days 1, 8,
and 15 of a 28-day cycle; (2) a phase I study of FDR gemcitabine at
doses ranging from 1000 to 1200mgm
 2 plus cisplatin 20mgm
 2,
both administered on days 1 and 8 of a 21-day cycle; and (3) a
phase II study of FDR gemcitabine at 1000mgm
 2 plus cisplatin at
20mgm
 2, both administered on days 1 and 8 of a 21-day cycle
(Table 1). Research support for these clinical trials was provided
by Eli Lilly. For study #1, only patients on the FDR gemcitabine
arm were eligible for inclusion in the current analysis, to maintain
as much uniformity as possible in patient and treatment
characteristics. A total of five different institutions enrolled
patients in one or more of these three studies.
To be eligible for inclusion in this analysis, subjects were
required to have a confirmed diagnosis of pancreatic adenocarci-
noma (either locally advanced or metastastic), a baseline serum
CA19-9 level greater than 75Ucm
 3 (two-fold the upper limit of
normal), no prior systemic therapy, and intact renal, hepatic, and
haematologic function. The absence of clinical or laboratory
evidence of biliary obstruction at baseline minimised the
possibility that CA19-9 levels would be attributable to this cause
rather than a true reflection of disease activity.
In each of these three clinical trials, the serum level of CA19-9
was measured at the start of each treatment cycle as part of the
ongoing clinical evaluation, approximately once every 3–4 weeks.
Given the retrospective nature of this study, with analysis of data
from three separate trials incorporating several institutions, it was
not possible to ascertain the uniformity of lab methodology
between different patients, as a single central laboratory was not
used. However, all serum CA19-9 measurements for any given
patient were routinely performed at the same laboratory, ensuring
some degree of intrapatient consistency. Patients with only one
CA19-9 measurement were categorised as nondecliners; the most
common reason for the lack of follow-up CA19-9 measurements in
these patients was death and/or early disease progression requiring
discontinuation of study treatment.
CA19-9 measurements over the entire course of treatment were
recorded. Descriptive statistics were used to record baseline
CA19-9 levels and the per cent change of this biomarker relative
to baseline. Subjects were placed in different categories based on
their level of biomarker decline achieved at any point throughout
the course of treatment (0–25% decline, 26–50% decline,
51–75% decline, and 76–100% decline, as well as no decline)
and by absolute threshold (greater than or less than 25% decline,
50% decline, and 75% decline). We did not require a sustained
biomarker decline (i.e. confirmation by two measurements spaced
at least 28 days apart) for this analysis.
w
2 tests were used to evaluate the statistical association between
baseline CA19-9 categorised into subgroups and subsequent
maximum per cent decline in biomarker decline. The relationships
between biomarker responses with patient outcomes, including
overall survival and time to treatment failure (TTF), and (where
available) objective radiographic response were then analysed. The
Kaplan–Meier product limit method was used to estimate the
probability of survival and of remaining free of treatment failure
accounting for censored observations with the median value used
to summarise the results. For comparisons of median survival
and TTF between defined subcategories, the Wilcoxon–Mann–
Whitney rank-sum log-rank test was performed. The Kaplan–
Meier method with log-rank test was used to evaluate significant
differences in survival and TTF accounting for censored data.
Cox’s proportional-hazard model was used to determine whether
CA19-9 was a significant predictor of both survival and TTF.
Statistical correlation between changes in CA19-9 and clinical
outcomes was confirmed using Spearman’s rank correlation.
RESULTS
Patient characteristics
Clinical and CA19-9 data were examined from a total of 103
patients from the three clinical studies. Of these, 76 patients
(73.8%) were eligible for inclusion in this study based on a
pretreatment serum CA19-9 measurement greater than two-fold
the upper limit of normal. Of the 76 eligible patients, 73 (96%) had
suspected or documented extrapancreatic metastases. The median
overall survival in this group of patients was 7.0 months (range,
0.2–35 months), and median TTF was 3.6 months (range, 0.2–29
months).
CA19-9 measurements
The median baseline CA19-9 level was 3052Ucm
 3 (range, 98–
832050Ucm
 3) (Table 1). Patients had serum CA19-9 measure-
ments approximately once per month, at the start of each
treatment cycle. The number of serial measurements ranged from
1 to 17 (median number of measurements, 4.5). There was a fairly
even distribution of degree of CA19-9 decline achieved at any point
during therapy compared with baseline when broken down by
degree of decline (0–25, 26–50, 51–75, and 76–100% decline)
Table 1 Baseline serum CA19-9 values of subjects in each study
Study description
Dates of
enrollment
No. of subjects
eligible for this
analysis
Median baseline
CA19-9
(Ucm
 3)
Baseline
CA19-9, range
(Ucm
 3)
Randomised phase II study of FDR gemcitabine vs standard infusion gemcitabine 1996–1999 25
a 3400 98–263000
Phase I study of FDR gemcitabine+cisplatin 1999–2000 10 3050 136–60000
Phase II study of FDR gemcitabine+cisplatin 2001–2004 41 2729 129–832050
Total 76 3052 98–832050
CA19-9¼carbohydrate antigen 19-9; FDR¼fixed-dose rate infusion of 10mgm
 2min
 1.
aTo maintain as uniform standards of treatment as possible across the three studies,
only patients on the FDR arm were included for this analysis.
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s(Table 2). The absolute numbers in each group, however, were
too small to determine any statistically significant difference
in distribution between subsets. In all, 25% of patients exhibited
no decline in their CA19-9 level at any point during
therapy (Table 2). Seven patients had only a solitary CA19-9
measurement at baseline (and, per study definition, were
classified as nondecliners). In terms of absolute thresholds of
CA19-9 decline, 68.4% of patients achieved at least a 25% decline
in CA19-9; 52.6% of patients achieved at least a 50% marker
decline; and 31.6% of patients achieved at least a 75% marker
decline (Table 3).
We also evaluated whether the baseline CA19-9 level had any
effect on the likelihood or degree of subsequent biomarker decline
by dividing subjects into quartiles according to their baseline
values (Table 4). w
2 tests showed no significant association between
baseline CA19-9 level and subsequent decline.
Relationship between CA19-9 and patient outcomes
Strong, statistically significant differences in median survival and
TTF were observed when patients were grouped by quartile
according to the percentage of CA19-9 decline (Po0.001 for both
survival and TTF) (Table 2). For example, patients with the
greatest degree of decline (475%) had a median survival and TTF
of 12.00 and 6.00 months, respectively, compared to 6.02 and 3.36
months in patients with only a 0–25% decline. Patients who did
not achieve any decline in CA19-9 at any point during the course
of treatment fared the most poorly, with a median survival of 4.31
months and a median TTF of 1.35 months. This trend toward
increasing survival held for each successive subset of biomarker
decline. The same trend of greater percentage biomarker decline
corresponding with improved clinical outcomes held true for
median times to treatment failure, with the exception of the (0–
25%) and (26–50%) subsets.
Additionally, we carried out sequential analyses examining
correlation between CA19-9 decline and patient outcomes, this
time using various thresholds of percentage decline as cutoff
points. These analyses demonstrated statistically significant
differences in both median survival and median TTF when
comparing patients who fell above vs below thresholds of 25, 50,
and 75% biomarker decline (Table 3). For example, using as a
benchmark a 50% decline in CA19-9 (as is frequently reported in
clinical trials), we found a fairly even distribution between those
who achieved at least a 50% decline vs those who did not (52.6 vs
47.4%). Those with 450% decline had a median survival of 10.80
months and a median TTF of 4.93 months compared to 5.82 and
2.07 months in patients who did not have at least a 50% decline.
Analysis of these data using Spearman’s rank correlation
confirmed the significant association between percentage CA19-9
change from baseline and both survival and the TTF (r¼ 0.345
(P¼0.004) and r¼ 0.322 (P¼0.007)).
Of note, 37 of the 76 patients (48.7%) demonstrated an early
biomarker response, defined as a decline in CA19-9 levels by a
minimum of 25% within the first two measurements after baseline
(data not shown). Additionally, 23 patients (30.3%) had an early
biomarker decline of at least 50%, and 11 (14.5%) showed at least a
75% early decline. Statistically significant differences in median
survival when comparing patients achieving early biomarker
response vs those who did not was found only when using the
25% threshold, although this is likely attributable to the small
numbers of patients achieving early biomarker response using the
50 and 75% thresholds.
Table 2 Analysis by CA19-9 subgroup
Group
Number of
patients
Median CA19-9
decline, absolute value
(Ucc
 3) (95% CI)
No. of pts.
censored for
survival
Median survival
(mos) (95% CI)
No. of pts.
censored for
TTF
Median time to
treatment failure
(mos) (95% CI)
No decline in CA19-9 19 (25.0%) N/A 1 (5.3%) 4.31 (3.00–5.20) 1 (5.3%) 1.35 (1.00–2.76)
0–25% decline 5 (6.6%) 114.0 (83–5500) 0 6.02 (3.80–9.67) 0 3.36 (1.38–5.72)
26–50% decline 12 (15.8%) 1424.0 (26–55000) 0 7.04 (5.16–10.00) 3 (25.0%) 3.60 (2.07–4.14)
51–75% decline 16 (21.1%) 2751.2 (160–279074) 2 (12.5%) 7.55 (5.16–10.80) 2 (12.5%) 3.80 (2.24–4.44)
475% decline 24 (31.6%) 3251.5 (236–263490) 2 (8.3%) 12.00 (9.21–13.59) 5 (20.8%) 6.00 (4.87–14.50)
Log-rank w
2 31.20 (df¼4, Po0.001) 50.34 (df¼4, Po0.001)
CA19-9¼carbohydrate antigen 19-9; CI¼confidence interval; mos¼months; TTF¼time to treatment failure; df¼degree of freedom.
Table 3 Analysis using specific thresholds for CA19-9 decline (reported results account for censored patients)
Yes No Log-rank v2
425% decline in CA19-9?
Number of patients (%) 52 (68.4%) 24 (31.6 %)
Median survival (mos) (95% CI) 9.61 (8.00–11.50) 4.64 (3.45–5.82) 24.07 (df¼1, Po0.001)
Median TTF (mos) (95% CI) 4.38 (3.88–6.00) 1.51 (1.00–2.76) 33.78 (df¼1, Po0.001)
450% decline in CA19-9?
Number of patients (%) 40 (52.6%) 36 (47.4%)
Median survival (mos) (95% CI) 10.80 (9.00–12.00) 5.82 (3.31–6.64) 14.58 (df¼1, Po0.001)
Median TTF (mos) (95% CI) 4.93 (4.00–6.15) 2.07 (1.41–3.36) 26.20 (df¼1, Po0.001)
475% decline in CA19-9?
Number of patients (%) 24 (31.6%) 52 (68.4%)
Median survival (mos) (95% CI) 12.00 (9.21–13.59) 6.00 (5.00–6.81) 16.20 (df¼1, Po0.001)
Median TTF (mos) (95% CI) 6.00 (4.87–14.50) 2.76 (1.80–3.60) 21.13 (df¼1, Po0.001)
CA19-9¼carbohydrate antigen 19-9; CI¼confidence interval; mos¼months; TTF¼time to treatment failure; df¼degree of freedom.
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sObjective response by RECIST criteria was not a defined end
point of any of the trials from which these data were collected;
however, unconfirmed responses were recorded as part of the
record-keeping for trials 1 and 3. In total, 11 unconfirmed
responses were tallied. Nine of these patients experienced a CA19-9
decline of 50–74%, and two patients experienced a CA19-9 decline
of greater than 75%. Conversely, no patient with less than a 50%
biomarker decline showed evidence of objective radiographic
response.
We used Cox’s multivariate proportional-hazard regression
model to evaluate the impact of three separate factors on clinical
outcomes: baseline CA19-9 concentration, the study the patient
was treated on, and percentage CA19-9 decline. Of these, only
percentage CA19-9 decline was strongly related to both survival
and TTF (data not shown).
DISCUSSION
A number of previous studies have provided justification for
measuring CA19-9 levels in patients with advanced pancreatic
cancer receiving either chemotherapy or radiation, both for
prognostic and for monitoring purposes. Patients with higher
CA19-9 levels prior to initiation of chemoradiation for locally
advanced disease have poorer outcomes in terms of both response
rates and overall survival (Ikeda et al, 2001; Micke et al, 2003b). A
lower CA19-9 level following completion of chemoradiation also
appears to correlate with survival (Micke et al, 2003a). Further-
more, the degree of change in CA19-9 levels during radiotherapy
may indicate how well a patient will fare, with two separate studies
demonstrating that either a 50 or a 75% biomarker decline
correlates with improved median survival time (Katz et al, 1998;
Okusaka et al, 1998).
With the widespread use of gemcitabine as the mainstay of
treatment in patients with advanced pancreatic cancer, recent
reports have begun to examine CA19-9 response to gemcitabine-
based treatments and whether kinetics of CA19-9 can serve as a
predictor of response to such treatments. A small retrospective
study by Saad et al (2002) of 28 patients with advanced pancreatic
cancer treated with gemcitabine found that lower pretreatment
levels of CA19-9, as well as a X50% decline in CA19-9 anytime
during treatment, correlated with better survival rates. Halm et al
(2000) examined 43 unresectable patients receiving gemcitabine
treatment and found that those with a 420% decrease of their
baseline CA19-9 level after 8 weeks of treatment had a longer
median survival than those with a rise or a decrease o20% (268 vs
110 days), a finding confirmed by Ziske et al (2003). This
biomarker response was in fact the only independent predictor
of survival in a multivariate analysis, showing a greater level of
significance than either objective tumour response or clinical
benefit response (Ziske et al, 2003). Heinemann and colleagues,
meanwhile, collected CA19-9 data from patients with advanced
pancreatic cancer receiving treatment on a study protocol using a
combination of cisplatin and gemcitabine (Stemmler et al, 2003).
CA19-9 responders, defined as those with a X50% decrease in
CA19-9 levels within 2 months after the start of treatment, survived
significantly longer than CA19-9 nonresponders (295 vs 174 days,
P¼0.022).
Our study represents the first to examine whether changes in
CA19-9 correlate with clinical outcomes in patients with advanced
pancreatic cancer treated with FDR gemcitabine. Infusion of
gemcitabine at an FDR is a strategy intended to optimise
pharmacokinetics of the drug (Grunewald et al, 1990). In a
recently published randomised phase II study, Tempero et al
(2003) reported that administration of gemcitabine by FDR
infusion resulted in superior outcomes in patients with advanced
pancreatic cancer compared to administration of this drug by
standard 30-min infusion.
We were specifically interested in examining how changes in
CA19-9 during treatment with FDR gemcitabine correlate with
clinical outcomes. Our response criteria were purposely broad in
that a decline from baseline in CA19-9 at any point in time after
initiation of treatment, whether early or late, was counted as a
biomarker response, although a significant proportion of patients
who responded did so within the first 2 months of therapy. While
we specifically did not require a sustained biomarker response
for the purposes of this study, all but seven patients did have a
sustained decline in CA19-9 confirmed over two consecutive
measurements. Analysis of our data even recategorising those
seven patients as nonresponders did not affect the strong
correlations found in this study.
Additionally, seven patients (9.2%) had only a solitary CA19-9
measurement at baseline. While we recognise the inherent bias in
including these patients in our analysis (follow-up measurements
were generally not obtained on these patients because of rapid
disease progression and/or clinical deterioration), we ultimately
decided to count them as biomarker nondecliners. Again,
reanalysis of our data if we excluded these patients did not affect
our study results in any way. Based on the results of our analysis, a
rising/nondeclining CA19-9 appears to be a clear indicator of early
progressive disease and to correlate with very poor clinical
outcomes. This finding may potentially be used in clinical practice
as justification for discontinuing systemic therapy early on.
One limitation of our analysis was the lack of uniformity in
treatment and in methodology for assaying CA19-9 levels between
different patients, given the retrospective and multi-institutional
nature of this analysis. However, we did intentionally select three
trials in which gemcitabine was consistently administered by FDR
infusion, and we believe that the addition of low-dose cisplatin
in two of the three trials should not have any substantial impact
on our findings. Additionally, each clinical trial did attempt to
maintain intrasubject consistency in terms of the laboratory where
each subject’s serial CA19-9 levels were measured. In the future,
clinical studies incorporating CA19-9 measurements should use a
Table 4 Likelihood of CA19-9 decline as a function of baseline CA19-9 value
Number of subjects with change in CA 19-9(%)
Baseline CA19-9 level Range (Ucc
 3) No decline 0–24% decline 25–49% decline 50–74% decline 75–100% decline Total
Lowest quartile 75–972 5 (26.3%) 3 (15.8%) 4 (21.1%) 3 (15.8%) 4 (21.1%) 19
2nd quartile 973–3052 6 (31.6%) 1 (5.3%) 2 (10.5%) 4 (21.1%) 6 (31.6%) 19
3rd quartile 3053–12815 4 (21.1%) 0 (0.0%) 2 (10.5%) 5 (26.3%) 8 (42.1%) 19
Highest quartile 412815 4 (21.1%) 1 (5.3%) 4 (21.1%) 4 (21.1%) 6 (31.6%) 19
Total 19 5 12 16 24 76
CA19-9¼carbohydrate antigen 19-9. The w
2 test shows that there is no significant association between baseline CA19-9 and likelihood or degree of marker decline (w
2¼7.556,
P¼0.82).
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sstandardised laboratory assay to ensure reliable results. Ideally,
approval of this test by the Food and Drug Administration for
monitoring patients on systemic therapy would further enhance
these efforts.
As all the clinical trials from which data were extracted did not
include objective response as an end point, we were only able to
use unconfirmed response data recorded by study investigators in
two of the three trials to correlate CA19-9 responses to radio-
graphic responses. Some might argue that objective responses
are the truest indicator of therapeutic activity. Nonetheless, the
outcome variables we chose for this study, particularly overall
survival, are the most relevant and clinically meaningful in terms
of deciding whether a particular agent is worthy of further study
or approval. We chose TTF rather than time to time to tumour
progression as the other major outcome variable to examine
because a number of patients on these trials discontinued study
treatment for reasons other than disease progression; thus,
censoring these data at those time points would have diluted our
numbers substantially.
This analysis demonstrates that declines in serum CA19-9 levels
of at least 25, 50, and 75% during treatment with a FDR
gemcitabine-containing regimen all correspond with improved
patient outcomes. Despite the relatively small numbers in this
analysis, the highly statistically significant findings indicate a
strong correlation between CA19-9 response and both survival
and TTF. When clinical trials report biomarker response data, they
generally use 50% as the threshold as an indicator of success.
Our analysis suggests that a 25% decline in CA19-9 may provide
adequate evidence for the clinical efficacy of a new therapeutic
agent or combination treatment strategy. Furthermore, grouping
the biomarker response by quartile demonstrates that greater
declines in CA19-9 are associated with improved clinical outcomes.
While this may be an intuitively obvious concept, ours is the first
study to provide conclusive evidence to support a clear and direct
correspondence between the degree of biomarker decline and how
well patients fare with their disease.
In conclusion, serial CA19-9 measurement represents a useful
prognostic tool in patients receiving chemotherapy for advanced
pancreatic cancer, with at least a 25% threshold in decline from
baseline correlating well with improved patient outcomes. While
our analysis was limited to patients receiving an FDR gemcitabine-
based regimen, there is little reason to suspect that our findings
would not be broadly applicable to other systemic therapies. Thus,
monthly CA19-9 measurements appear to be justified for
predicting outcomes to therapy and tailoring treatment decisions,
and should be considered as a surrogate end point in clinical trials
for the selection of new treatments.
ACKNOWLEDGEMENTS
We thank Elizabeth Dito, RN, and Brian Schillinger, RN, for their
assistance in caring for the study patients and keeping meticulous
track of clinical data; F Gary Renshaw, DO, for providing us with
some of the study data; and Vivian Weinberg, PhD, for additional
statistical help. The research support for this work was provided
by Eli Lilly and the Rombauer Pancreatic Cancer Research Fund.
REFERENCES
Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B,
Space S, Westrick B, Schoemaker H, Zurawski Jr VR (1983) Radio-
immunometric assay for a monoclonal antibody-defined tumor marker,
CA 19-9. Clin Chem 29: 549–552
Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P,
Plunkett W (1990) Pharmacologically directed design of the dose rate
and schedule of 20,20-difluorodeoxycytidine (Gemcitabine) administra-
tion in leukemia. Cancer Res 50: 6823–6826
Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V (2000)
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts
survival time in patients with advanced pancreatic cancer. Br J Cancer 82:
1013–1016
Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T (2001) Prognostic
factors in patients with locally advanced pancreatic carcinoma receiving
chemoradiotherapy. Cancer 91: 490–495
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ,
Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30
Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L (1998) Prognostic value
of CA 19-9 levels in patients with carcinoma of the pancreas treated with
radiotherapy. Int J Radiat Oncol Biol Phys 41: 393–396
Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981) Specific antigen in
serum of patients with colon carcinoma. Science 212: 53–55
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P
(1979) Colorectal carcinoma antigens detected by hybridoma antibodies.
Somatic Cell Genet 5: 957–971
Micke O, Bruns F, Kurowski R, Horst E, deVries AF, Hausler JW, Willich N,
Schafer U (2003a) Predictive value of carbohydrate antigen 19-9 in
pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol
Biol Phys 57: 90–97
Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N (2003b) CA
19-9 in the therapy monitoring and follow-up of locally advanced cancer
of the exocrine pancreas treated with radiochemotherapy. Anticancer Res
23: 835–840
Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O,
Matsuno S, Yokoyama S (1998) Tumor markers in evaluating the
response to radiotherapy in unresectable pancreatic cancer. Hepatogas-
troenterology 45: 867–872
Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM,
Wanebo HJ (1996) A rationale for expanding the endpoints for clinical
trials in advanced pancreatic carcinoma. Cancer 78: 627–632
Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz
A, Simon SD, Gansl RC (2002) Pretreatment CA 19-9 level as a prognostic
factor in patients with advanced pancreatic cancer treated with
gemcitabine. Int J Gastrointest Cancer 32: 35–41
Steinberg W (1990) The clinical utility of the CA 19-9 tumor-associated
antigen. Am J Gastroenterol 85: 350–355
Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM,
Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K,
Garbrecht M, Heinemann V (2003) Are serial CA 19-9 kinetics helpful
in predicting survival in patients with advanced or metastatic pancreatic
cancer treated with gemcitabine and cisplatin? Onkologie 26: 462–467
Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H,
Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-
intense gemcitabine: thirty-minute infusion and fixed dose rate infusion
in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402–3408
Yeo C, Tempero M, Abrams R (2002) Pancreas cancer: clinical manage-
ment. In Gastrointestinal Oncology: Principles and Practices Tepper J (ed)
Philadelphia: Lippincott Williams and Wilkins
Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J,
Sauerbruch T, Schmidt-Wolf IG (2003) Prognostic value of CA 19-9 levels
in patients with inoperable adenocarcinoma of the pancreas treated with
gemcitabine. Br J Cancer 89: 1413–1417
CA19-9 as a surrogate in pancreatic cancer
AH Ko et al
199
British Journal of Cancer (2005) 93(2), 195–199 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s